Results 221 to 230 of about 235,827 (297)

One‐Stage Posterior‐to‐Anterior Ankle Arthroscopy Using a Single Operative Setup and Patient Repositioning Technique: A Technical Note

open access: yesArthroscopy Techniques, EarlyView.
Abstract This technical note describes a 1‐stage arthroscopic technique for the management of combined posterior and anterior ankle pathology that preserves standard patient positioning while reducing operative time and material costs. The procedure begins with posterior ankle arthroscopy performed in the prone position using standard posterior portals.
Julien Paquot, David Roche, Ronny Lopes
wiley   +1 more source

Summary of Best Evidence for Wound Management in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. [PDF]

open access: yesActa Derm Venereol
Kong S   +12 more
europepmc   +1 more source

Self‐ and Caregiver‐Reported Choice‐Making in Autistic Adults: Development and Validation of the AASPIRE–Choices and Decisions Scale

open access: yesAutism Research, EarlyView.
ABSTRACT Self‐determination has been assessed as an internal psychological construct. External factors may also affect self‐determination, but opportunities to make choices and decisions remain understudied. We developed and evaluated the AASPIRE‐Choices and Decisions Scale (AASPIRE‐CDS), a new measure of autistic adults' opportunities to make choices ...
So Yoon Kim   +14 more
wiley   +1 more source

Awareness of the Black Triangle Scheme among healthcare professionals and consumers in Australia: A mixed‐methods study exploring reporting intentions and suggested improvements

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims The Black Triangle Scheme, introduced in 2018 in Australia, does not appear to have increased the quantity of adverse drug event (ADE) reports. This study evaluated healthcare professionals' (HCPs') and consumers' awareness of the scheme, its influence on intentions for future ADE reporting, and suggested improvements.
Eyob Alemayehu Gebreyohannes   +7 more
wiley   +1 more source

HLA‐B*15:21 carrier status is a susceptibility factor of carbamazepine‐induced nonimmediate cutaneous adverse reactions in HLA‐B*15:02‐negative patients: A retrospective cohort study

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
After HLA‐B*15:02 screening, the residual risk of carbamazepine‐induced nonimmediate cutaneous adverse reactions is 0.059. Among these HLA‐B*15:02‐negative cases, HLA‐B*15:11 and HLA‐B*15:21 carrier status significantly increases the risk of carbamazepine‐induced nonimmediate cADR.
Warit Ruanglertboon   +11 more
wiley   +1 more source

Home - About - Disclaimer - Privacy